Literature DB >> 28847300

Analgesics in Pregnancy: An Update on Use, Safety and Pharmacokinetic Changes in Drug Disposition.

Hayley R Price1, Abby C Collier1.   

Abstract

BACKGROUND: Although medications should only be prescribed in pregnancy if benefits to the mother outweigh the risk to the fetus, drug use in pregnancy especially prescribed and over-the-counter analgesics, is very common.
OBJECTIVE: The objective of this review is to present an update on known changes in analgesic disposition in pregnancy caused by pharmacokinetic mechanisms.
METHOD: Herein, we discuss a wide range of medical, biomedical and scientific literature that includes reports from the fields of dentistry, general medicine, obstetrics and gynecology, pharmacology and toxicology to provide an update on the use (including indications, contraindications and concerns) of major classes of analgesics during human pregnancy.
RESULTS: Over 50% of analgesics are in pregnancy category C, and even more category D specifically in the third trimester. Changes in renal filtration, cardiac output, plasma protein concentration and plasma volume particularly affect analgesics and dose adjustments may be necessary to maintain therapeutic concentrations in pregnant woman, and/or to protect the developing fetus.
CONCLUSION: Analgesics are one of the most frequently used drug classes in pregnancy. More than 60% of women self-report using analgesics while pregnant, both prescribed and by self-medication. For the majority of analgesics available (excepting acetaminophen and the NSAIDs, and to a lesser extent certain opioids), good prospective clinical trials documenting pharmacokinetic changes do not exist. More research is needed in both the scientific and clinical community to understand the risks and benefits of analgesic use in pregnancy, particularly as prevalence is rising. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Addiction; metabolism; neonatal abstinence syndrome; obstetrics; pain; teratogenesis.

Mesh:

Substances:

Year:  2017        PMID: 28847300     DOI: 10.2174/1381612823666170825123754

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  Maternal paracetamol intake and fetal ductus arteriosus constriction/closure: comprehensive signal evaluation using the Austin Bradford Hill criteria.

Authors:  Manfred Hauben; Stephen Bai; Eric Hung; Kasia Lobello; Charles Tressler; Vincent P Zucal
Journal:  Eur J Clin Pharmacol       Date:  2021-01-07       Impact factor: 2.953

2.  Prevalence and safety of prescription medicine use during pregnancy in the Republic of Suriname in the year 2017: a pharmacoepidemiological analysis.

Authors:  Vinoj H Sewberath Misser; Arti Shankar; Ashna Hindori-Mohangoo; Jeffrey Wickliffe; Maureen Lichtveld; Dennis R A Mans
Journal:  Adv Pharmacoepidemiol Drug Saf       Date:  2021-09-20

3.  Detection and quantitation of non-steroidal anti-inflammatory drug use close to the time of birth using umbilical cord tissue.

Authors:  Hayley R Price; Dickson Lai; Hugh Kim; Tricia E Wright; Michael W H Coughtrie; Abby C Collier
Journal:  Toxicol Rep       Date:  2020-09-08

Review 4.  Screening Pregnant Women and Their Neonates for Illicit Drug Use: Consideration of the Integrated Technical, Medical, Ethical, Legal, and Social Issues.

Authors:  Hayley R Price; Abby C Collier; Tricia E Wright
Journal:  Front Pharmacol       Date:  2018-08-28       Impact factor: 5.810

5.  Opioid exposure during pregnancy and the risk of congenital malformation: a meta-analysis of cohort studies.

Authors:  Xinrui Wang; Yushu Wang; Borui Tang; Xin Feng
Journal:  BMC Pregnancy Childbirth       Date:  2022-05-11       Impact factor: 3.105

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.